A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of Dose limiting toxicities
Incidence of frequency of Dose limiting toxicities during first 4 weeks will be measured according to the commen terminology criteria for adverse events (CTCAE).
United States: Food and Drug Administration